URGN Insider Trading Activity and SEC Form 4 Filings
URGN insider trading summary
Over the past 12 months, insiders at UroGen Pharma Ltd. (URGN) reported 12 sales worth $4.6M by 2 insiders and no open-market purchases on SEC Form 4. Net insider selling was $4.6M.
Latest URGN insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 20, 2026 | Mark Schoenberg | Chief Medical Officer | Sell | $2.9M (60,677 @ $47.05) |
| Jul 9, 2026 | Mark Schoenberg | Chief Medical Officer | Sell | $400K (10,000 @ $40.00) |
| Jun 22, 2026 | Mark Schoenberg | Chief Medical Officer | Sell | $350K (10,000 @ $35.01) |
| Jun 8, 2026 | Mark Schoenberg | Chief Medical Officer | Sell | $143K (5,222 @ $27.30) |
| May 8, 2026 | Mark Schoenberg | Chief Medical Officer | Sell | $300K (10,000 @ $30.00) |
| Feb 3, 2026 | Jason Drew Smith | General Counsel | Sell | $32K (1,608 @ $19.69) |
| Feb 3, 2026 | Mark Schoenberg | Chief Medical Officer | Sell | $73K (3,686 @ $19.69) |
| Feb 3, 2026 | Mark Schoenberg | Chief Medical Officer | Sell | $36K (1,844 @ $19.69) |
| Feb 3, 2026 | Mark Schoenberg | Chief Medical Officer | Sell | $36K (1,843 @ $19.69) |
| Feb 3, 2026 | Jason Drew Smith | General Counsel | Sell | $52K (2,654 @ $19.69) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.